|By PR Newswire||
|September 2, 2014 03:00 AM EDT||
LONDON, Sept. 2, 2014 /PRNewswire/ -- Based on its recent analysis of the mammalian contract manufacturing services market, Frost & Sullivan recognises Goodwin Biotechnology with the 2014 Global Frost & Sullivan Award for Customer Value Leadership. Goodwin Biotechnology's reputation as one of the most trusted providers of mammalian contract manufacturing and development services has been built on more than 20 years of experience in the bioprocess development and cGMP manufacturing of mammalian cell culture-derived monoclonal antibodies (mAbs), vaccines, and recombinant proteins, and more than 10 years pioneering the field of bioconjugation.
Goodwin Biotechnology championed the concept of 'full integration' in the biopharmaceutical contract manufacturing space. It is a one-stop shop, offering its partners a comprehensive range of services from cell line development and proof-of-concept projects to bioprocess development and the manufacture of material for preclinical / Tox studies as well as early to late phase clinical trials.
Goodwin Biotechnology strives to be a highly flexible partner with its clients by finding customized solutions for the distinctive needs of every project and ensuring smooth implementation all throughout the lifecycle of an engagement. Furthermore, it has enhanced its brand value on a global basis by maintaining high levels of transparency and responsiveness while focusing on quality, and working within budgets and timelines.
The core services offered by Goodwin Biotechnology include cell line development through collaborations, cell culture and purification process development, cell banking, process scale-up, engineering runs for toxicology study materials, and strict adherence to current good manufacturing practices (cGMP) for manufacturing and providing Fill / Finish services for biopharmaceutical candidates used in human clinical trials. The company has also established best-in-class processes for the production of antibody drug conjugates (ADCs), cytotoxic ADCs (CADCs), antibody-chelator conjugates (for radioimmunoconjugates) and other bioconjugates.
"These core services are fully complemented and enhanced by the company's analytical and formulation development capabilities as well as its quality assurance, quality control, regulatory and project management capabilities," said Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. "The complete and fully-integrated services offered by Goodwin Biotechnology reduce the supply chain complexities and timeline for clients to efficiently meet their preclinical and clinical needs."
"We at Goodwin Biotechnology are honored to be recognized for such a prestigious award, which showcases our orientation towards providing our clients with the best overall value proposition," noted Karl Pinto, CEO of Goodwin Biotechnology. "It is a testament to the company's rich and distinguished history, coupled with its innovative, state-of-the-art technologies, and highly skilled scientists that enables us to meet the expectations of customers across the globe and at various stages of their respective product development cycles. Having addressed challenges pertaining to the manufacturing of complex biological molecules, such as monoclonal antibodies, recombinant therapeutic proteins, vaccines and cytotoxic ADCs (CADCs), Goodwin Biotechnology helps our clients formulate a strategic approach with particular emphasis on critical protein product characterization, process development, and cGMP manufacturing for regulatory compliance."
"Goodwin Biotechnology's time-tested expertise with various host cell types and process optimisation techniques enables seamless technology transfers between R&D and GMP manufacturing for clinical studies," added Chidambaram. "It is one of the few contract manufacturing organisations to have installed capabilities for a number of robust and reproducible cell cultivation technologies, including disposable bioreactors such as, WAVE, perfusion, and stainless steel tank bioreactors."
At the start of every project, Goodwin Biotechnology focuses on optimising and refining the processes to maximize productivity and ensure seamless scale up. Towards that end, the company has hands-on experience in several chromatographic techniques including affinity, ion exchange, hydrophobic interaction, mixed mode, and size-exclusion chromatography. In addition, its ultrafiltration/diafiltration (UF/DF) processes use tangential flow filtration (TFF) technologies in both flat-plate and hollow-fiber formats.
Goodwin Biotechnology also addresses complex issues associated with antibody drug conjugates, including linker design, drug payload selection, and antibody stability in the production of multi-gram lots of conjugated antibodies used globally in clinical trials. Apart from its rich and varied expertise in protein modification through chemical conjugation and enzymatic digestion methods, Goodwin Biotechnology also offers unique specialties such as the production of Fab and F(ab')2 fragments and their subsequent purification as per client specifications.
Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. The award recognises the company's inordinate focus on enhancing the value that its customers receive, beyond simply good customer service, leading to improved customer retention and, ultimately, customer base expansion.
Frost & Sullivan Best Practices awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
About Goodwin Biotechnology
Goodwin Biotechnology is a world-class CMO that offers a Single Source Solution™ through partnerships with clients for cell line development or exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and Antibody Drug Conjugates (ADCs) and other Biologic Drug Conjugates for early and late stage clinical trials. By working with Goodwin Biotechnology, our clients can enhance the value of their product candidates with clear development and manufacturing strategies as well as a road map to meet the highest quality product requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical approval pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients' lives. With over 20 years of experience as an independent contract manufacturer, Goodwin Biotechnology has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Additional information may be found at http://www.GoodwinBio.com.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Frost & Sullivan
Goodwin Biotechnology, Inc.
Best Practices, Frost & Sullivan
Manager of Business Development
P: +44 (0) 207 915 7867
SOURCE Frost & Sullivan
Oct. 4, 2015 12:00 AM EDT Reads: 362
Oct. 4, 2015 12:00 AM EDT Reads: 226
Oct. 3, 2015 11:00 PM EDT Reads: 266
Oct. 3, 2015 09:00 PM EDT Reads: 339
Oct. 3, 2015 06:00 PM EDT Reads: 287
Oct. 3, 2015 05:00 PM EDT Reads: 305
Oct. 3, 2015 05:00 PM EDT Reads: 312
Oct. 3, 2015 03:00 PM EDT Reads: 260
Oct. 3, 2015 03:00 PM EDT Reads: 265
Oct. 3, 2015 02:15 PM EDT Reads: 545
Oct. 3, 2015 01:15 PM EDT Reads: 558
Oct. 3, 2015 01:00 PM EDT Reads: 243
Oct. 3, 2015 01:00 PM EDT Reads: 641
Oct. 3, 2015 12:45 PM EDT Reads: 222
Mobile messaging has been a popular communication channel for more than 20 years. Finnish engineer Matti Makkonen invented the idea for SMS (Short Message Service) in 1984, making his vision a reality on December 3, 1992 by sending the first message ("Happy Christmas") from a PC to a cell phone. Since then, the technology has evolved immensely, from both a technology standpoint, and in our everyday uses for it. Originally used for person-to-person (P2P) communication, i.e., Sally sends a text...
Oct. 3, 2015 12:00 PM EDT Reads: 132